Polatuzumab vedotin is a prescription medicine used to treat adults with diffuse large B-cell lymphoma (DLBCL) that has not gotten better with other treatments or has come back after other treatments. Polatuzumab vedotin is given together with bendamustine and a rituximab product. It is not known if Polatuzumab vedotin is safe and effective in children.
Polatuzumab vedotin, sold under the brand name Polivy, is a medication used to treat a specific type of cancer called diffuse large B-cell lymphoma (DLBCL) [1]. Here's a breakdown of its key features:
Type of Drug: Polatuzumab vedotin is classified as an antibody-drug conjugate (ADC) [1].
How it Works: ADCs are a type of targeted therapy that combines two components:
- Monoclonal antibody (polatuzumab): This acts like a smart missile, specifically attaching to a protein (CD79b) found on the surface of malignant B-cells [1, 3].
- Cytotoxic agent (monomethyl auristatin E, MMAE): Once attached, the ADC delivers the MMAE, a cell-killing agent, directly to the cancer cells [1]. This targeted approach aims to minimize harm to healthy cells.
Uses: Polatuzumab vedotin is primarily approved for two lymphoma treatments:
- Relapsed or refractory DLBCL: In adults whose DLBCL has come back after treatment or hasn't responded well to initial therapy [2]. It's usually used in combination with other chemotherapy drugs like bendamustine and rituximab [2].
- Previously untreated DLBCL: Recently, polatuzumab vedotin was approved in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for first-line treatment of specific high-risk DLBCL in adults [5].
Important Considerations:
- Prescription Medication: Polatuzumab vedotin is a powerful medication and should only be used under the supervision of a qualified healthcare professional.
- Serious Side Effects: Like many cancer treatments, polatuzumab vedotin can cause serious side effects, including low blood cell counts (neutropenia, thrombocytopenia), peripheral neuropathy (numbness, tingling, pain in hands and feet), and infections [2, 5].
- Not for Everyone: It's not suitable for everyone with DLBCL. Doctors will consider factors like a patient's overall health and other medical conditions before prescribing this medication.